Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission
A partir d'échantillons de sérum prélevés, au moment du diagnostic et à l'observation d'une rémission complète, sur 23 patients atteints d'un myélome multiple et à partir d'échantillons prélevés sur 31 témoins, cette étude évalue l'intérêt de la spectroscopie par RMN 1H pour identifier des biomarqueurs associés au diagnostic et à la réponse thérapeutique
Purpose: Multiple myeloma (MM) remains an incurable disease. New approaches to develop better tools for improving patient prognostication and monitoring treatment efficacy are very much needed. In this study, we aimed to evaluate the potential of metabolomics by 1H-NMR to provide information on metabolic profiles that could be useful in the management of MM.
Experimental Design: Serum samples were collected from MM patients at the time of diagnosis and after achieving complete remission. A matched control set of samples was also included in the study. The 1H-NMR measurements used to obtain the metabolic profile for each patient were followed by the application of univariate and multivariate statistical analyses to determine significant differences.
Results: Metabolic profiles of MM patients at diagnosis exhibited higher levels of isoleucine, arginine, acetate, phenylalanine and tyrosine, and decreased levels of 3-hydroxybutyrate, lysine, glutamine, and some lipids compared with the control set. A similar analysis performed in MM patients after achieving complete remission indicated that some of the metabolic changes (i.e., glutamine, cholesterol, lysine) observed at diagnosis displayed a variation in the opposite direction upon responding to treatment, thus contributing to MM patients having a closer metabolic profile to those of healthy individuals after the disappearance of major disease manifestations.
Conclusions: The results highlight the potential that metabolic profiles obtained by 1H-NMR in identifying MM biomarkers that may be useful to objectively discriminate individuals with and without MM, and monitor response to treatment.
Clinical Cancer Research , article en libre accès, 2013